- Home
- IBG vs ALLR Comparison
IBG vs ALLR Comparison
Compare IBG & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- ALLR
- Stock Information
- Founded
- IBG 2018
- ALLR 2004
- Country
- IBG Australia
- ALLR United States
- Employees
- IBG N/A
- ALLR N/A
- Industry
- IBG Beverages (Production/Distribution)
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- ALLR Health Care
- Exchange
- IBG Nasdaq
- ALLR Nasdaq
- Market Cap
- IBG 5.4M
- ALLR 15.8M
- IPO Year
- IBG 2024
- ALLR N/A
- Fundamental
- Price
- IBG $0.57
- ALLR $0.94
- Analyst Decision
- IBG Strong Buy
- ALLR Strong Buy
- Analyst Count
- IBG 1
- ALLR 1
- Target Price
- IBG N/A
- ALLR $9.00
- AVG Volume (30 Days)
- IBG 529.3K
- ALLR 367.8K
- Earning Date
- IBG 08-26-2025
- ALLR 08-15-2025
- Dividend Yield
- IBG N/A
- ALLR N/A
- EPS Growth
- IBG N/A
- ALLR N/A
- EPS
- IBG N/A
- ALLR N/A
- Revenue
- IBG $2,931,243.00
- ALLR N/A
- Revenue This Year
- IBG N/A
- ALLR N/A
- Revenue Next Year
- IBG N/A
- ALLR N/A
- P/E Ratio
- IBG N/A
- ALLR N/A
- Revenue Growth
- IBG N/A
- ALLR N/A
- 52 Week Low
- IBG $0.44
- ALLR $0.61
- 52 Week High
- IBG $3.35
- ALLR $6.00
- Technical
- Relative Strength Index (RSI)
- IBG 41.82
- ALLR 47.03
- Support Level
- IBG $0.54
- ALLR $0.85
- Resistance Level
- IBG $0.72
- ALLR $1.01
- Average True Range (ATR)
- IBG 0.07
- ALLR 0.05
- MACD
- IBG -0.01
- ALLR -0.01
- Stochastic Oscillator
- IBG 10.71
- ALLR 47.55
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.